Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 87

1.

ROS1-rearranged Non-small-cell Lung Cancer is Associated With a High Rate of Venous Thromboembolism: Analysis From a Phase II, Prospective, Multicenter, Two-arms Trial (METROS).

Chiari R, Ricciuti B, Landi L, Morelli AM, Delmonte A, Spitaleri G, Cortinovis DL, Lamberti G, Facchinetti F, Pilotto S, Verusio C, Chella A, Bonanno L, Galetta D, Cappuzzo F.

Clin Lung Cancer. 2019 Jun 18. pii: S1525-7304(19)30154-8. doi: 10.1016/j.cllc.2019.06.012. [Epub ahead of print]

PMID:
31607443
2.

Prognostic Value of QFR Measured Immediately After Successful Stent Implantation: The International Multicenter Prospective HAWKEYE Study.

Biscaglia S, Tebaldi M, Brugaletta S, Cerrato E, Erriquez A, Passarini G, Ielasi A, Spitaleri G, Di Girolamo D, Mezzapelle G, Geraci S, Manfrini M, Pavasini R, Barbato E, Campo G.

JACC Cardiovasc Interv. 2019 Sep 21. pii: S1936-8798(19)31302-0. doi: 10.1016/j.jcin.2019.06.003. [Epub ahead of print]

PMID:
31563688
3.

Correction to: Gr-MDSC-linked asset as a potential immune biomarker in pretreated NSCLC receiving nivolumab as second-line therapy.

Passaro A, Mancuso P, Gandini S, Spitaleri G, Labanca V, Guerini-Rocco E, Barberis M, Catania C, Del Signore E, de Marinis F, Bertolini F.

Clin Transl Oncol. 2019 Aug 20. doi: 10.1007/s12094-019-02198-5. [Epub ahead of print]

PMID:
31432394
4.

The Desire for Life and Motherhood Despite Metastatic Lung Cancer.

Catania C, Del Signore E, Spitaleri G.

JAMA Oncol. 2019 Aug 15. doi: 10.1001/jamaoncol.2019.2588. [Epub ahead of print] No abstract available.

PMID:
31415084
5.

Gr-MDSC-linked asset as a potential immune biomarker in pretreated NSCLC receiving nivolumab as second-line therapy.

Passaro A, Mancuso P, Gandini S, Spitaleri G, Labanca V, Guerini-Rocco E, Barberis M, Catania C, Del Signore E, de Marinis F, Bertolini F.

Clin Transl Oncol. 2019 Jun 28. doi: 10.1007/s12094-019-02166-z. [Epub ahead of print] Erratum in: Clin Transl Oncol. 2019 Aug 20;:.

PMID:
31254252
6.

Immunotherapy in Non-Small-Cell Lung Cancer Patients With Performance Status 2: Clinical Decision Making With Scant Evidence.

Passaro A, Spitaleri G, Gyawali B, de Marinis F.

J Clin Oncol. 2019 Aug 1;37(22):1863-1867. doi: 10.1200/JCO.18.02118. Epub 2019 Apr 17. No abstract available.

PMID:
30995172
7.

Activity of EGFR TKIs in Caucasian Patients With NSCLC Harboring Potentially Sensitive Uncommon EGFR Mutations.

Passaro A, Prelaj A, Bonanno L, Tiseo M, Tuzi A, Proto C, Chiari R, Rocco D, Genova C, Sini C, Cortinovis D, Pilotto S, Landi L, Bennati C, Camerini A, Toschi L, Putzu C, Cerea G, Spitaleri G, Cappuzzo F, de Marinis F.

Clin Lung Cancer. 2019 Mar;20(2):e186-e194. doi: 10.1016/j.cllc.2018.11.005. Epub 2018 Nov 20.

PMID:
30563752
8.

Ensartinib (X-396) a novel drug for anaplastic lymphoma kinasepositive non-small cell lung cancer patients: we need smart trials to avoid wasting good bullets.

Spitaleri G, Passaro A, de Marinis F.

Chin Clin Oncol. 2018 Oct 15. pii: cco.2018.09.03. doi: 10.21037/cco.2018.09.03. [Epub ahead of print] No abstract available.

9.

Applicability of a prognostic CT-based radiomic signature model trained on stage I-III non-small cell lung cancer in stage IV non-small cell lung cancer.

de Jong EEC, van Elmpt W, Rizzo S, Colarieti A, Spitaleri G, Leijenaar RTH, Jochems A, Hendriks LEL, Troost EGC, Reymen B, Dingemans AC, Lambin P.

Lung Cancer. 2018 Oct;124:6-11. doi: 10.1016/j.lungcan.2018.07.023. Epub 2018 Jul 20.

10.

Comparison of Verapamil versus Heparin as Adjunctive Treatment for Transradial Coronary Procedures: The VERMUT Study.

Tebaldi M, Biscaglia S, Tumscitz C, Del Franco A, Gallo F, Spitaleri G, Fileti L, Serenelli M, Tonet E, Erriquez A, Campo G, Ferrari R.

Cardiology. 2018;140(2):74-82. doi: 10.1159/000488852. Epub 2018 Jun 13.

PMID:
29898437
11.

5'-nucleotidase cN-II emerges as a new predictive biomarker of response to gemcitabine/platinum combination chemotherapy in non-small cell lung cancer.

Toffalorio F, Santarpia M, Radice D, Jaramillo CA, Spitaleri G, Manzotti M, Catania C, Jordheim LP, Pelosi G, Peters GJ, Tibaldi C, Funel N, Spaggiari L, de Braud F, De Pas T, Giovannetti E.

Oncotarget. 2018 Feb 16;9(23):16437-16450. doi: 10.18632/oncotarget.24505. eCollection 2018 Mar 27.

12.

Role of ST-Segment Resolution in Patients With ST-Segment Elevation Myocardial Infarction Treated With Primary Percutaneous Coronary Intervention (from the 5-Year Outcomes of the EXAMINATION [Evaluation of the Xience-V Stent in Acute Myocardial Infarction] Trial).

Spitaleri G, Brugaletta S, Scalone G, Moscarella E, Ortega-Paz L, Pernigotti A, Gomez-Lara J, Cequier A, Iñiguez A, Serra A, Jiménez-Quevedo P, Mainar V, Campo G, Tespili M, den Heijer P, Bethencourt A, Vazquez N, Valgimigli M, Serruys PW, Sabaté M.

Am J Cardiol. 2018 May 1;121(9):1039-1045. doi: 10.1016/j.amjcard.2018.01.015. Epub 2018 Feb 7.

PMID:
29544865
13.

How should I treat a bioresorbable vascular scaffold edge restenosis and intra-scaffold dissection?

Fallesen CO, Antonsen L, Thayssen P, Jensen LO, Lee PH, Lee SW, Park SJ, Moscarella E, Spitaleri G, Brugaletta S.

EuroIntervention. 2018 Feb 20;13(14):1730-1734. doi: 10.4244/EIJ-D-17-00309. No abstract available.

14.

Quantitative Flow Ratio Identifies Nonculprit Coronary Lesions Requiring Revascularization in Patients With ST-Segment-Elevation Myocardial Infarction and Multivessel Disease.

Spitaleri G, Tebaldi M, Biscaglia S, Westra J, Brugaletta S, Erriquez A, Passarini G, Brieda A, Leone AM, Picchi A, Ielasi A, Girolamo DD, Trani C, Ferrari R, Reiber JHC, Valgimigli M, Sabatè M, Campo G.

Circ Cardiovasc Interv. 2018 Feb;11(2):e006023. doi: 10.1161/CIRCINTERVENTIONS.117.006023.

PMID:
29449325
15.

Correlates of non-target vessel-related adverse events in patients with ST-segment elevation myocardial infarction: insights from five-year follow-up of the EXAMINATION trial.

Spitaleri G, Moscarella E, Brugaletta S, Pernigotti A, Ortega-Paz L, Gomez-Lara J, Cequier A, Iñiguez A, Serra A, Jiménez-Quevedo P, Mainar V, Campo G, Tespili M, den Heijer P, Bethencourt A, Vazquez N, Valgimigli M, Serruys PW, Sabaté M.

EuroIntervention. 2018 Mar 20;13(16):1939-1945. doi: 10.4244/EIJ-D-17-00608.

16.

A first-in-human phase I study of SAR125844, a selective MET tyrosine kinase inhibitor, in patients with advanced solid tumours with MET amplification.

Angevin E, Spitaleri G, Rodon J, Dotti K, Isambert N, Salvagni S, Moreno V, Assadourian S, Gomez C, Harnois M, Hollebecque A, Azaro A, Hervieu A, Rihawi K, De Marinis F.

Eur J Cancer. 2017 Dec;87:131-139. doi: 10.1016/j.ejca.2017.10.016. Epub 2017 Nov 14.

17.

Brigatinib for the treatment of ALK-positive advanced non-small cell lung cancer patients.

Passaro A, Prelaj A, Pochesci A, Spitaleri G, Rossi G, Del Signore E, Catania C, de Marinis F.

Drugs Today (Barc). 2017 Aug;53(8):435-446. doi: 10.1358/dot.2017.53.8.2676119. Review.

PMID:
29119148
18.

Lung Tissue Injury as an Atypical Response to Nivolumab in Non-Small Cell Lung Cancer.

Rampinelli C, Spitaleri G, Passaro A, Pochesci A, Ancona E, De Marinis F.

Am J Respir Crit Care Med. 2017 Nov 15;196(10):1349-1350. doi: 10.1164/rccm.201705-0875IM. No abstract available.

PMID:
28910131
19.

Methods to assess bioresorbable vascular scaffold devices behaviour after implantation.

Pernigotti A, Moscarella E, Spitaleri G, Scardino C, Ishida K, Brugaletta S.

J Thorac Dis. 2017 Aug;9(Suppl 9):S959-S968. doi: 10.21037/jtd.2017.06.110. Review.

20.

Impact of Body Mass Index on 5-Year Clinical Outcomes in Patients With ST-Segment Elevation Myocardial Infarction After Everolimus-Eluting or Bare-Metal Stent Implantation.

Moscarella E, Spitaleri G, Brugaletta S, Sentí Farrarons S, Pernigotti A, Ortega-Paz L, Cequier A, Iñiguez A, Serra A, Jiménez-Quevedo P, Mainar V, Campo G, Tespili M, den Heijer P, Bethencourt A, Vazquez N, Valgimigli M, Serruys PW, Sabaté M.

Am J Cardiol. 2017 Nov 1;120(9):1460-1466. doi: 10.1016/j.amjcard.2017.07.040. Epub 2017 Jul 31.

PMID:
28864322
21.

A counseling program on nuisance bleeding improves quality of life in patients on dual antiplatelet therapy: A randomized controlled trial.

Biscaglia S, Tonet E, Pavasini R, Serenelli M, Bugani G, Cimaglia P, Gallo F, Spitaleri G, Del Franco A, Aquila G, Vieceli Dalla Sega F, Tebaldi M, Tumscitz C, Ferrari R, Campo G.

PLoS One. 2017 Aug 23;12(8):e0182124. doi: 10.1371/journal.pone.0182124. eCollection 2017.

22.

Outcomes of First-Generation EGFR-TKIs Against Non-Small-Cell Lung Cancer Harboring Uncommon EGFR Mutations: A Post Hoc Analysis of the BE-POSITIVE Study.

Pilotto S, Rossi A, Vavalà T, Follador A, Tiseo M, Galetta D, Morabito A, Di Maio M, Martelli O, Caffo O, Piovano PL, Cortinovis D, Zilembo N, Casartelli C, Banna GL, Ardizzoia A, Barzelloni ML, Bearz A, Genestreti G, Mucciarini C, Filipazzi V, Menis J, Rizzo E, Barbieri F, Rijavec E, Cecere F, Spitaleri G, Bria E, Novello S.

Clin Lung Cancer. 2018 Jan;19(1):93-104. doi: 10.1016/j.cllc.2017.05.016. Epub 2017 Jun 1.

PMID:
28645631
23.

Targeting EGFR T790M mutation in NSCLC: From biology to evaluation and treatment.

Passaro A, Guerini-Rocco E, Pochesci A, Vacirca D, Spitaleri G, Catania CM, Rappa A, Barberis M, de Marinis F.

Pharmacol Res. 2017 Mar;117:406-415. doi: 10.1016/j.phrs.2017.01.003. Epub 2017 Jan 12. Review.

PMID:
28089942
24.

Amino terminal pro brain natriuretic peptide predicts all-cause mortality in patients with chronic obstructive pulmonary disease: Systematic review and meta-analysis.

Pavasini R, Tavazzi G, Biscaglia S, Guerra F, Pecoraro A, Zaraket F, Gallo F, Spitaleri G, Contoli M, Ferrari R, Campo G.

Chron Respir Dis. 2017 May;14(2):117-126. doi: 10.1177/1479972316674393. Epub 2016 Dec 15. Review.

25.

Prospective Identification of Stent Fracture by Enhanced Stent Visualization System During Percutaneous Coronary Intervention.

Biscaglia S, Tebaldi M, Tumscitz C, Pavasini R, Marchesini J, Gallo F, Spitaleri G, Zaraket F, Serenelli M, Cimaglia P, Bugani G, Campo G.

Circ J. 2016 Dec 22;81(1):82-89. doi: 10.1253/circj.CJ-16-0785. Epub 2016 Nov 17.

26.

Personalized treatment in advanced ALK-positive non-small cell lung cancer: from bench to clinical practice.

Passaro A, Lazzari C, Karachaliou N, Spitaleri G, Pochesci A, Catania C, Rosell R, de Marinis F.

Onco Targets Ther. 2016 Oct 17;9:6361-6376. eCollection 2016. Review.

27.

Afatinib for the first-line treatment of patients with metastatic EGFR-positive NSCLC: a look at the data.

Passaro A, Pochesci A, Spitaleri G, Catania C, Noberasco C, Del Signore E, de Marinis F.

Expert Rev Clin Pharmacol. 2016 Oct;9(10):1283-1288. doi: 10.1080/17512433.2016.1233059. Epub 2016 Sep 20.

PMID:
27626838
28.

Predischarge screening for chronic obstructive pulmonary disease in patients with acute coronary syndrome and smoking history.

Campo G, Pavasini R, Barbetta C, Maietti E, Mascetti S, Biscaglia S, Zaraket F, Spitaleri G, Gallo F, Tonet E, Papi A, Ferrari R, Contoli M.

Int J Cardiol. 2016 Nov 1;222:806-812. doi: 10.1016/j.ijcard.2016.08.030. Epub 2016 Aug 4.

PMID:
27522379
29.

First-line treatment in NSCLC harboring EGFR common mutations: EGFR TKI in monotherapy or in combination with anti-VEGF?

Passaro A, Spitaleri G, de Marinis F.

Expert Rev Anticancer Ther. 2016 Aug;16(8):799-801. doi: 10.1080/14737140.2016.1210007. Epub 2016 Jul 15. No abstract available.

PMID:
27386899
30.

Dramatic Antitumor Activity of Nivolumab in Advanced HER2-Positive Lung Cancer.

Catania C, Passaro A, Rocco EG, Spitaleri G, Barberis M, Noberasco C, Signore ED, Travaini L, de Marinis F.

Clin Lung Cancer. 2016 Sep;17(5):e179-e183. doi: 10.1016/j.cllc.2016.05.004. Epub 2016 Jun 4. No abstract available.

PMID:
27349506
31.

[Immunotherapy in non-small cell lung cancer: evolution of knowledge and clinical advances].

Pochesci A, Passaro A, Catania C, Noberasco C, Del Signore E, Spitaleri G, De Marinis F.

Recenti Prog Med. 2016 Apr;107(4):186-92. doi: 10.1701/2218.23930. Italian.

PMID:
27093328
32.

Afatinib in first-line setting for NSCLC harbouring common EGFR mutations: new light after the preliminary results of LUX-Lung 7?

Passaro A, Pochesci A, Spitaleri G, Catania C, Noberasco C, Del Signore E, de Marinis F.

J Thorac Dis. 2016 Mar;8(3):E217-20. doi: 10.21037/jtd.2016.02.21.

33.

BE-POSITIVE: Beyond progression after tyrosine kinase inhibitor in EGFR- positive non small cell lung cancer patients: Results from a multicenter Italian observational study.

Vavalà T, Follador A, Tiseo M, Galetta D, Morabito A, Di Maio M, Martelli O, Caffo O, Piovano PL, Cortinovis D, Zilembo N, Casartelli C, Banna GL, Ardizzoia A, Barzelloni ML, Bearz A, Genestreti G, Mucciarini C, Filipazzi V, Menis J, Rizzo E, Barbieri F, Rijavec E, Cecere F, Bria E, Spitaleri G, Rossi A, Novello S.

Lung Cancer. 2016 May;95:73-81. doi: 10.1016/j.lungcan.2016.02.011. Epub 2016 Feb 26.

34.

Improved health perception after genetic counselling for women at high risk of breast and/or ovarian cancer: construction of new questionnaires--an Italian exploratory study.

Catania C, Feroce I, Barile M, Goldhirsch A, De Pas T, de Braud F, Boselli S, Adamoli L, Radice D, Rossi A, Spitaleri G, Noberasco C, Bonanni B.

J Cancer Res Clin Oncol. 2016 Mar;142(3):633-48. doi: 10.1007/s00432-015-2062-7. Epub 2015 Nov 17.

PMID:
26577826
35.

A phase I, dose-escalation study of volasertib combined with nintedanib in advanced solid tumors.

de Braud F, Cascinu S, Spitaleri G, Pilz K, Clementi L, Liu D, Sikken P, De Pas T.

Ann Oncol. 2015 Nov;26(11):2341-6. doi: 10.1093/annonc/mdv354. Epub 2015 Sep 22.

PMID:
26395347
36.

Inactivity of imatinib in gastrointestinal stromal tumors (GISTs) harboring a KIT activation-loop domain mutation (exon 17 mutation pN822K).

Spitaleri G, Biffi R, Barberis M, Fumagalli C, Toffalorio F, Catania C, Noberasco C, Lazzari C, de Marinis F, De Pas T.

Onco Targets Ther. 2015 Aug 18;8:1997-2003. doi: 10.2147/OTT.S81558. eCollection 2015.

37.

CT Radiogenomic Characterization of EGFR, K-RAS, and ALK Mutations in Non-Small Cell Lung Cancer.

Rizzo S, Petrella F, Buscarino V, De Maria F, Raimondi S, Barberis M, Fumagalli C, Spitaleri G, Rampinelli C, De Marinis F, Spaggiari L, Bellomi M.

Eur Radiol. 2016 Jan;26(1):32-42. doi: 10.1007/s00330-015-3814-0. Epub 2015 May 9.

PMID:
25956936
38.

Molecular features and clinical outcome of lung malignancies in very young people.

Catania C, Botteri E, Barberis M, Conforti F, Toffalorio F, De Marinis F, Boselli S, Noberasco C, Delmonte A, Spitaleri G, Spaggiari L, Rotmensz N, Passaro A, Bazolli B, Alfieri M, Manzotti M, Fumagalli C, Milani A, De Pas T.

Future Oncol. 2015;11(8):1211-21. doi: 10.2217/fon.15.10.

PMID:
25832878
39.

Progression-Free and Overall Survival in ALK-Positive NSCLC Patients Treated with Sequential Crizotinib and Ceritinib.

Gainor JF, Tan DS, De Pas T, Solomon BJ, Ahmad A, Lazzari C, de Marinis F, Spitaleri G, Schultz K, Friboulet L, Yeap BY, Engelman JA, Shaw AT.

Clin Cancer Res. 2015 Jun 15;21(12):2745-52. doi: 10.1158/1078-0432.CCR-14-3009. Epub 2015 Feb 27.

40.

Erlotinib efficacy in NSCLC patients with high polysomy of chromosome 7 and EGFR/KRas wild-type tumors.

Toffalorio F, de Marinis F, Conforti F, Spitaleri G, Catania C, Noberasco C, Lazzari C, Vecchio F, Stufano V, Barberis M, De Pas T.

J Thorac Oncol. 2015 Feb;10(2):392-6. doi: 10.1097/JTO.0000000000000355.

41.

The tumor-targeting immunocytokine F16-IL2 in combination with doxorubicin: dose escalation in patients with advanced solid tumors and expansion into patients with metastatic breast cancer.

Catania C, Maur M, Berardi R, Rocca A, Giacomo AM, Spitaleri G, Masini C, Pierantoni C, González-Iglesias R, Zigon G, Tasciotti A, Giovannoni L, Lovato V, Elia G, Menssen HD, Neri D, Cascinu S, Conte PF, Braud Fd.

Cell Adh Migr. 2015;9(1-2):14-21. doi: 10.4161/19336918.2014.983785.

42.

Antitumor activity of sorafenib and imatinib in a patient with thymic carcinoma harboring c-KIT exon 13 missense mutation K642E.

Catania C, Conforti F, Spitaleri G, Barberis M, Preda L, Noberasco C, Lazzari C, Toffalorio F, de Marinis F, Manzotti M, De Pas TM.

Onco Targets Ther. 2014 May 8;7:697-702. doi: 10.2147/OTT.S58902. eCollection 2014.

43.

Phase ib of sorafenib in combination with everolimus in patients with advanced solid tumors, selected on the basis of molecular targets.

Toffalorio F, Spitaleri G, Catania C, Dal Zotto L, Noberasco C, Delmonte A, Santarpia M, Vecchio F, Brunelli V, Rampinelli C, Barberis M, Fumagalli C, Zucchetti M, Zangarini M, Diena T, Danesi R, de Braud F, De Pas T.

Oncologist. 2014 Apr;19(4):344-5. doi: 10.1634/theoncologist.2013-0335. Epub 2014 Mar 27.

44.

Gene expression profiling reveals GC and CEACAM1 as new tools in the diagnosis of lung carcinoids.

Toffalorio F, Belloni E, Barberis M, Bucci G, Tizzoni L, Pruneri G, Fumagalli C, Spitaleri G, Catania C, Melotti F, Pelicci PG, Spaggiari L, De Pas T.

Br J Cancer. 2014 Mar 4;110(5):1244-9. doi: 10.1038/bjc.2014.41. Epub 2014 Feb 11.

45.

Targeting ALK in patients with advanced non small cell lung cancer: biology, diagnostic and therapeutic options.

Lazzari C, Spitaleri G, Catania C, Barberis M, Noberasco C, Santarpia M, Delmonte A, Toffalorio F, Conforti F, De Pas TM.

Crit Rev Oncol Hematol. 2014 Mar;89(3):358-65. doi: 10.1016/j.critrevonc.2013.09.003. Epub 2013 Sep 26. Review.

PMID:
24156959
46.

The choice of whether to participate in a phase I clinical trial: increasing the awareness of patients with cancer. An exploratory study.

Catania C, Radice D, Spitaleri G, Adamoli L, Noberasco C, Delmonte A, Vecchio F, de Braud F, Toffalorio F, Goldhirsch A, De Pas T.

Psychooncology. 2014 Mar;23(3):322-9. doi: 10.1002/pon.3424. Epub 2013 Oct 10.

PMID:
24123459
47.

Breast phyllodes tumor: a review of literature and a single center retrospective series analysis.

Spitaleri G, Toesca A, Botteri E, Bottiglieri L, Rotmensz N, Boselli S, Sangalli C, Catania C, Toffalorio F, Noberasco C, Delmonte A, Luini A, Veronesi P, Colleoni M, Viale G, Zurrida S, Goldhirsch A, Veronesi U, De Pas T.

Crit Rev Oncol Hematol. 2013 Nov;88(2):427-36. doi: 10.1016/j.critrevonc.2013.06.005. Epub 2013 Jul 17. Review.

48.

EGFR tyrosine kinase inhibitors beyond focal progression obtain a prolonged disease control in patients with advanced adenocarcinoma of the lung.

Conforti F, Catania C, Toffalorio F, Duca M, Spitaleri G, Barberis M, Noberasco C, Delmonte A, Santarpia M, Lazzari C, De Pas TM.

Lung Cancer. 2013 Sep;81(3):440-444. doi: 10.1016/j.lungcan.2013.05.019. Epub 2013 Jun 27.

PMID:
23810573
49.

Phase I/II study of the tumour-targeting human monoclonal antibody-cytokine fusion protein L19-TNF in patients with advanced solid tumours.

Spitaleri G, Berardi R, Pierantoni C, De Pas T, Noberasco C, Libbra C, González-Iglesias R, Giovannoni L, Tasciotti A, Neri D, Menssen HD, de Braud F.

J Cancer Res Clin Oncol. 2013 Mar;139(3):447-55. doi: 10.1007/s00432-012-1327-7. Epub 2012 Nov 17.

PMID:
23160853
50.

Sarcoma of the breast: outcome and reconstructive options.

Toesca A, Spitaleri G, De Pas T, Botteri E, Gentilini O, Bottiglieri L, Rotmentsz N, Sangalli C, Marrazzo E, Cassano E, Veronesi P, Rietjens M, Luini A.

Clin Breast Cancer. 2012 Dec;12(6):438-44. doi: 10.1016/j.clbc.2012.09.008. Epub 2012 Oct 11.

PMID:
23062708

Supplemental Content

Loading ...
Support Center